BeiGene BGB-16673 CLL/SLL Phase 1 Clinical Trial Results 2024

Clinical trial results for BeiGene's BTK degrader BGB-16673 in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The study demonstrates the drug's efficacy in patients resistant to covalent and noncovalent BTK inhibitors through targeted protein degradation via polyubiquitination.